Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AdAlta Ltd. ( (AU:1AD) ) has issued an update.
AdAlta’s cellular immunotherapy subsidiary AdCella is set to benefit from new US FDA guidance that introduces greater flexibility in manufacturing and control requirements for cell and gene therapies, reducing cost and timelines between early and later-stage clinical trials and aligning with AdCella’s focus on scalable, automated, and portable manufacturing processes. The company has also advanced its collaboration with Shanghai Cell Therapy Group by making a US$0.5 million milestone payment for BZDS1901 and bolstered its cash position with an additional A$0.15 million R&D Tax Incentive refund tied to overseas CAR-T research, underscoring progress in executing its ‘East to West’ strategy and enhancing the commercial attractiveness and partnerability of its pipeline.
The most recent analyst rating on (AU:1AD) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on AdAlta Ltd. stock, see the AU:1AD Stock Forecast page.
More about AdAlta Ltd.
AdAlta Limited is an ASX-listed, clinical-stage biotechnology company focused on developing effective cellular immunotherapies for solid cancers, a segment that represents the vast majority of cancer cases yet remains poorly served by current cell therapies. Through its ‘East to West’ strategy, the company in-licenses differentiated T cell therapy products from Asian originators and progresses them through US FDA-regulated manufacturing and Phase I trials in Australia, positioning assets for on-licensing to larger biopharmaceutical companies, while also advancing its first-in-class fibrosis fusion protein AD-214 for partnering.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$13.77M
Learn more about 1AD stock on TipRanks’ Stock Analysis page.